Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Cell Mol Med ; 21(12): 3612-3625, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28941013

RESUMEN

The fundamental mechanisms underlying erosive oesophagitis and subsequent development of Barrett's oesophagus (BO) are poorly understood. Here, we investigated the contribution of specific components of the gastric refluxate on adhesion molecules involved in epithelial barrier maintenance. Cell line models of squamous epithelium (HET-1A) and BO (QH) were used to examine the effects of bile acids on cell adhesion to extracellular matrix proteins (Collagen, laminin, vitronectin, fibronectin) and expression of integrin ligands (α3 , α4, α5 , α6 and αν ). Experimental findings were validated in human explant oesophageal biopsies, a rat model of gastroesophageal reflux disease (GORD) and in patient tissue microarrays. The bile acid deoxycholic acid (DCA) specifically reduced adhesion of HET-1A cells to vitronectin and reduced cell-surface expression of integrin-αν via effects on endocytic recycling processes. Increased expression of integrin-αv was observed in ulcerated tissue in a rat model of GORD and in oesophagitis and Barrett's intestinal metaplasia patient tissue compared to normal squamous epithelium. Increased expression of integrin-αν was observed in QH BO cells compared to HET-1A cells. QH cells were resistant to DCA-mediated loss of adhesion and reduction in cell-surface expression of integrin-αν . We demonstrated that a specific component of the gastric refluxate, DCA, affects the epithelial barrier through modulation of integrin αν expression, providing a novel mechanism for bile acid-mediated erosion of oesophageal squamous epithelium and promotion of BO. Strategies aimed at preventing bile acid-mediated erosion should be considered in the clinical management of patients with GORD.


Asunto(s)
Esófago de Barrett/metabolismo , Ácido Desoxicólico/farmacología , Células Epiteliales/efectos de los fármacos , Esofagitis/metabolismo , Reflujo Gastroesofágico/metabolismo , Integrina alfaV/genética , Animales , Esófago de Barrett/genética , Esófago de Barrett/patología , Adhesión Celular , Línea Celular , Colágeno/química , Modelos Animales de Enfermedad , Células Epiteliales/metabolismo , Células Epiteliales/patología , Esofagitis/genética , Esofagitis/patología , Fibronectinas/química , Reflujo Gastroesofágico/genética , Reflujo Gastroesofágico/patología , Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Humanos , Integrina alfaV/metabolismo , Integrinas/genética , Integrinas/metabolismo , Laminina/química , Permeabilidad/efectos de los fármacos , Transporte de Proteínas , Ratas , Análisis de Matrices Tisulares , Vitronectina/química
2.
Foot (Edinb) ; 47: 101809, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33957526

RESUMEN

CASE: Lesions, which commonly grow and protrude beneath the distal end of a toe nail and present to the podiatrist or foot and ankle surgeon, include subungual exostosis or enchondroma and a Nora lesion. Neurothekeoma is a benign dermal tumour of the peripheral nerve sheath that usually affects the skin of the head, neck, shoulders and arms. It occurs less commonly in the lower limbs and has only been reported twice in a subungual location. A case of subungual neurothekeoma that recurred twice due to inadequate margins of resection is presented. CONCLUSION: Although rare, neurothekeoma should be included in the differential diagnosis of a subungual lesion. Histopathological diagnosis is reached by differential immunostaining. Adequate clear margins of resection are recommended to prevent recurrence.


Asunto(s)
Exostosis , Enfermedades de la Uña , Neurotecoma , Neoplasias Cutáneas , Diagnóstico Diferencial , Exostosis/diagnóstico , Humanos , Enfermedades de la Uña/diagnóstico , Enfermedades de la Uña/cirugía , Recurrencia Local de Neoplasia , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/cirugía
3.
Clin Cancer Res ; 18(2): 380-91, 2012 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-22090358

RESUMEN

PURPOSE: Cancer cells have been shown to be more susceptible to Ran knockdown than normal cells. We now investigate whether Ran is a potential therapeutic target of cancers with frequently found mutations that lead to higher Ras/MEK/ERK [mitogen-activated protein/extracellular signal-regulated kinase (ERK; MEK)] and phosphoinositide 3-kinase (PI3K)/Akt/mTORC1 activities. EXPERIMENTAL DESIGN: Apoptosis was measured by flow cytometry [propidium iodide (PI) and Annexin V staining] and MTT assay in cancer cells grown under different conditions after knockdown of Ran. The correlations between Ran expression and patient survival were examined in breast and lung cancers. RESULTS: Cancer cells with their PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways inhibited are less susceptible to Ran silencing-induced apoptosis. K-Ras-mutated, c-Met-amplified, and Pten-deleted cancer cells are also more susceptible to Ran silencing-induced apoptosis than their wild-type counterparts and this effect is reduced by inhibitors of the PI3K/Akt/mTORC1 and MEK/ERK pathways. Overexpression of Ran in clinical specimens is significantly associated with poor patient outcome in both breast and lung cancers. This association is dramatically enhanced in cancers with increased c-Met or osteopontin expression, or with oncogenic mutations of K-Ras or PIK3CA, all of which are mutations that potentially correlate with activation of the PI3K/Akt/mTORC1 and/or Ras/MEK/ERK pathways. Silencing Ran also results in dysregulation of nucleocytoplasmic transport of transcription factors and downregulation of Mcl-1 expression, at the transcriptional level, which are reversed by inhibitors of the PI3K/Akt/mTORC1 and MEK/ERK pathways. CONCLUSION: Ran is a potential therapeutic target for treatment of cancers with mutations/changes of expression in protooncogenes that lead to activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.


Asunto(s)
Apoptosis/genética , Neoplasias de la Mama/metabolismo , Carcinoma/metabolismo , Neoplasias Pulmonares/metabolismo , Sistema de Señalización de MAP Quinasas , Proteína de Unión al GTP ran/metabolismo , Transporte Activo de Núcleo Celular , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/patología , Carcinoma/mortalidad , Carcinoma/patología , Línea Celular Tumoral , Fosfatidilinositol 3-Quinasa Clase I , Femenino , Eliminación de Gen , Regulación Neoplásica de la Expresión Génica , Técnicas de Silenciamiento del Gen , Humanos , Estimación de Kaplan-Meier , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/patología , Diana Mecanicista del Complejo 1 de la Rapamicina , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Complejos Multiproteicos , Mutación , Proteína 1 de la Secuencia de Leucemia de Células Mieloides , Invasividad Neoplásica , Osteopontina/genética , Osteopontina/metabolismo , Fosfohidrolasa PTEN/genética , Fosfohidrolasa PTEN/metabolismo , Fosfatidilinositol 3-Quinasas/genética , Fosfatidilinositol 3-Quinasas/metabolismo , Proteínas/metabolismo , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Proteínas Proto-Oncogénicas c-met/genética , Proteínas Proto-Oncogénicas c-met/metabolismo , Proteínas Proto-Oncogénicas p21(ras) , Interferencia de ARN , Transducción de Señal , Serina-Treonina Quinasas TOR , Transcripción Genética , Proteína de Unión al GTP ran/genética , Proteínas ras/genética , Proteínas ras/metabolismo
4.
Mol Imaging Biol ; 12(5): 509-19, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20013063

RESUMEN

PURPOSE: Animal models are important for pre-clinical assessment of novel therapies in metastatic bladder cancer. The F344/AY-27 model involves orthotopic colonisation with AY-27 tumour cells which are syngeneic to F344 rats. One disadvantage of the model is the unknown status of colonisation between instillation and sacrifice. Non-invasive optical imaging using red fluorescence reporters could potentially detect tumours in situ and would also reduce the number of animals required for each experiment. MATERIALS AND METHODS: AY-27 cells were stably transfected with either pDsRed2-N1 or pcDNA3.1tdTomato. The intensity and stability of fluorescence in the resultant AY-27/DsRed2-N1 and AY-27/tdTomato stable cell lines were compared using Xenogen IVIS®200 and Olympus IX51 systems. RESULTS: AY-27/tdTomato fluorescence intensity was 60-fold brighter than AY-27/DsRed2-N1 and was sustained in AY-27/tdTomato cells following freezing and six subsequent sub-cultures. After sub-cutaneous injection, fluorescence intensity from AY-27/tdTomato cells was threefold stronger than that detected from AY-27/DsRed2-N1 cells. IVIS®200 detected fluorescence from AY-27/tdTomato and AY-27/DsRed2-N1 cells colonising resected and exteriorised bladders, respectively. However, the deep-seated position of the bladder precluded in vivo imaging. Characteristics of AY-27/tdTomato cells in vitro and in tumours colonising F344 rats resembled those of parental AY-27 cells. Tumour transformation was observed in the bladders colonised with AY-27/DsRed2-N1 cells. CONCLUSIONS: In vivo whole-body imaging of internal red fluorescent animal tumours should use pcDNA3.1tdTomato rather than pDsRed2-N1. Optical imaging of deep-seated organs in larger animals remains a challenge which may require proteins with brighter red or far-red fluorescence and/or alternative approaches.


Asunto(s)
ADN de Plantas/genética , Solanum lycopersicum/genética , Neoplasias de la Vejiga Urinaria/metabolismo , Animales , Línea Celular Tumoral , Modelos Animales de Enfermedad , Fluorescencia , Ratas , Ratas Endogámicas F344 , Ratas Transgénicas , Neoplasias de la Vejiga Urinaria/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA